Altogether, the findings suggest that GPR4 is a pro-inflammatory receptor involved in COVID-19 and GPR4 antagonism may be exploited as a potential therapeutic approach to dampen the hyperinflammatory response of COVID-19 to alleviate disease severity. The gene discussed is GPR4; the disease is COVID-19.